NG2 proteoglycan-binding peptides target tumor neovasculature.
暂无分享,去创建一个
R Pasqualini | E Ruoslahti | W Arap | E. Ruoslahti | W. Arap | R. Pasqualini | W. Stallcup | M A Burg | W B Stallcup | M. Burg | E. Ruoslahti | Michael A. Burg | Renata Pasqualini
[1] V. Alakhov,et al. Multidrug-resistance drug-binding peptides generated by using a phage display library. , 1998, European journal of biochemistry.
[2] A. Nishiyama,et al. Expression of NG2 proteoglycan causes retention of type VI collagen on the cell surface. , 1993, Molecular biology of the cell.
[3] J. Prince,et al. The primary structure of NG2, a novel membrane-spanning proteoglycan , 1991, The Journal of cell biology.
[4] D. Ruiter,et al. Differential expression of markers for endothelial cells, pericytes, and basal lamina in the microvasculature of tumors and granulation tissue. , 1991, The American journal of pathology.
[5] R. Kerbel. A cancer therapy resistant to resistance , 1997, Nature.
[6] H. Dvorak,et al. Penetration of Tumor Tissue by Antibodies and Other Immunoproteins , 1991, Annals of the New York Academy of Sciences.
[7] C. Heldin,et al. Interaction between NG2 proteoglycan and PDGF α‐receptor on O2A progenitor cells is required for optimal response to PDGF , 1996, Journal of neuroscience research.
[8] J. Folkman. Angiogenesis in cancer, vascular, rheumatoid and other disease , 1995, Nature Medicine.
[9] P. Nowell. The clonal evolution of tumor cell populations. , 1976, Science.
[10] H. Dvorak,et al. Identification and characterization of the blood vessels of solid tumors that are leaky to circulating macromolecules. , 1988, The American journal of pathology.
[11] N. Kaplan,et al. Monoclonal antibody and an antibody-toxin conjugate to a cell surface proteoglycan of melanoma cells suppress in vivo tumor growth. , 1983, Proceedings of the National Academy of Sciences of the United States of America.
[12] Erkki Ruoslahti,et al. αv Integrins as receptors for tumor targeting by circulating ligands , 1997, Nature Biotechnology.
[13] W. Stallcup,et al. Participation of the NG2 proteoglycan in rat aortic smooth muscle cell responses to platelet-derived growth factor. , 1995, Experimental cell research.
[14] B R Johansson,et al. Pericyte loss and microaneurysm formation in PDGF-B-deficient mice. , 1997, Science.
[15] W. Stallcup,et al. Expression of the NG2 proteoglycan enhances the growth and metastatic properties of melanoma cells , 1998, Journal of cellular physiology.
[16] F. Burrows,et al. Eradication of large solid tumors in mice with an immunotoxin directed against tumor vasculature. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[17] K. Sekiguchi,et al. Novel peptide ligands for integrin alpha 6 beta 1 selected from a phage display library. , 1996, Journal of biochemistry.
[18] R. Reisfeld,et al. Doxorubicin conjugated with a monoclonal antibody directed to a human melanoma-associated proteoglycan suppresses the growth of established tumor xenografts in nude mice. , 1988, Proceedings of the National Academy of Sciences of the United States of America.
[19] S Ferrone,et al. Expression of the high molecular weight melanoma-associated antigen by pericytes during angiogenesis in tumors and in healing wounds. , 1989, The American journal of pathology.
[20] Thomas Boehm,et al. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance , 1997, Nature.
[21] P. Lindahl,et al. Not all myofibroblasts are alike: revisiting the role of PDGF‐A and PDGF‐B using PDGF‐targeted mice , 1998, Current opinion in nephrology and hypertension.
[22] R. Timpl,et al. Binding of the NG2 Proteoglycan to Type VI Collagen and Other Extracellular Matrix Molecules* , 1996, The Journal of Biological Chemistry.
[23] I. Bernstein,et al. Human homologue of the rat chondroitin sulfate proteoglycan, NG2, detected by monoclonal antibody 7.1, identifies childhood acute lymphoblastic leukemias with t(4;11)(q21;q23) or t(11;19)(q23;p13) and MLL gene rearrangements. , 1996, Blood.
[24] Erkki Ruoslahti,et al. Organ targeting In vivo using phage display peptide libraries , 1996, Nature.
[25] J. H. Butler,et al. High affinity type I interleukin 1 receptor antagonists discovered by screening recombinant peptide libraries. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[26] D. Sims,et al. The pericyte--a review. , 1986, Tissue & cell.
[27] F. Ruggiero,et al. The Membrane-spanning Proteoglycan NG2 Binds to Collagens V and VI through the Central Nonglobular Domain of Its Core Protein* , 1997, The Journal of Biological Chemistry.
[28] R. Reisfeld,et al. Cell-Associated Proteoglycans in Human Malignant Melanoma , 1987 .
[29] A. Nishiyama,et al. A central segment of the NG2 proteoglycan is critical for the ability of glioma cells to bind and migrate toward type VI collagen. , 1997, Experimental cell research.
[30] Erkki Ruoslahti,et al. Phage Libraries Displaying Cyclic Peptides with Different Ring Sizes: Ligand Specificities of the RGD-Directed Integrins , 1995, Bio/Technology.
[31] R. Kerbel,et al. Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti‐cancer therapeutic agents , 1991, BioEssays : news and reviews in molecular, cellular and developmental biology.
[32] P. Itin,et al. Molecular cloning of a human melanoma-associated chondroitin sulfate proteoglycan. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[33] B. Zetter,et al. Tumor interactions with the vasculature: angiogenesis and tumor metastasis. , 1990, Biochimica et biophysica acta.
[34] R Pasqualini,et al. Molecular heterogeneity of the vascular endothelium revealed by in vivo phage display. , 1998, The Journal of clinical investigation.
[35] R. Kerbel,et al. Consequences of angiogenesis for tumor progression, metastasis and cancer therapy. , 1995, Anti-cancer drugs.
[36] J. Iida,et al. Spreading and focal contact formation of human melanoma cells in response to the stimulation of both melanoma-associated proteoglycan (NG2) and alpha 4 beta 1 integrin. , 1995, Cancer research.
[37] H. Dvorak,et al. Pathogenesis of tumor stroma generation: a critical role for leaky blood vessels and fibrin deposition. , 1989, Biochimica et biophysica acta.
[38] J. Iida,et al. Spreading and Focal Contact Formation of Human Melanoma Cells in Response to the Stimulation of Both Melanoma-associated Proteoglycan (NG2) and α4β1 Integrin , 1995 .
[39] R. Reisfeld,et al. Inhibition of anchorage-independent growth of human melanoma cells by a monoclonal antibody to a chondroitin sulfate proteoglycan. , 1983, Journal of the National Cancer Institute.
[40] C. T. Baillie,et al. Tumour vasculature--a potential therapeutic target. , 1995, British Journal of Cancer.
[41] R Pasqualini,et al. Chemotherapy targeted to tumor vasculature. , 1998, Current opinion in oncology.
[42] K. Hirschi,et al. Control of angiogenesis by the pericyte: molecular mechanisms and significance. , 1997, EXS.
[43] S. Rosenberg,et al. High-affinity urokinase receptor antagonists identified with bacteriophage peptide display. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[44] W. Arap,et al. Integrin-binding peptides derived from phage display libraries. , 1999, Methods in molecular biology.
[45] H. Dvorak,et al. Structure of solid tumors and their vasculature: implications for therapy with monoclonal antibodies. , 1991, Cancer cells.
[46] G. P. Smith,et al. Libraries of peptides and proteins displayed on filamentous phage. , 1993, Methods in enzymology.
[47] T Ochiya,et al. PDGF (alpha)-receptor is unresponsive to PDGF-AA in aortic smooth muscle cells from the NG2 knockout mouse. , 1999, Journal of cell science.
[48] M. Melamed,et al. Surface antigens of melanomas and melanocytes defined by mouse monoclonal antibodies: specificity analysis and comparison of antigen expression in cultured cells and tissues. , 1985, Cancer research.
[49] M. Schrappe,et al. Correlation of chondroitin sulfate proteoglycan expression on proliferating brain capillary endothelial cells with the malignant phenotype of astroglial cells. , 1991, Cancer research.
[50] L. Miller,et al. Therapy of patients with malignant melanoma using a monoclonal antimelanoma antibody-ricin A chain immunotoxin. , 1987, Cancer research.
[51] C. Dean,et al. The chondroitin sulfate proteoglycan NG2 is a tumour‐specific antigen on the chemically induced rat chondrosarcoma HSN , 1994, International journal of cancer.